Intelligence » Hepatitis B » Last Week

Subscribe to get latest posts via email or subscribe to a RSS feed.

Serum viral load predicts HBV flares in patients who cease therapy

Thursday, August 17, 2017 -- Persistent or severe hepatitis followed virological relapse among patients who discontinued treatment with Baraclude for chronic hepatitis B, according to recently published data. Serum viral load at treatment cessation predicted clinical flares.“It remains controversial whether [chronic hepatitis B] patients can safely discontinue [nucleos(t)ide analogues] before HBsAg loss. How to predict durable off-therapy remission has become the focus of intense research,” the researchers wrote. “Our study adds to current understanding about the risk and risk stratification of clinical hepatitis subsequent to virological relapse in [chronic HBV] patients who stop taking [Baraclude].”